Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.

hbed-cc
adenocarcinoma
stereotactic body radiation therapy
metastasis
adenocarcinoma of prostate
  • 16 views
  • 05 Aug, 2020
Cost Talk: Discussing Cancer Care Costs

The purpose of this study is to investigate whether an encounter decision aid (used during a consultation) containing cost information about options, combined with clinician training about cost discussions and available financial resources, influence surgeon-patient cost conversations, referrals to address costs, patients' financial stress, and high-quality decision-making for patients with …

prostate specific antigen
cancer care
  • 0 views
  • 16 Feb, 2024
  • 1 location
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:

5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic boost.

adenocarcinoma
stereotactic body radiation therapy
adenocarcinoma of prostate
  • 0 views
  • 16 Feb, 2024
  • 1 location
Impact of Acetazolamide in Reducing Referred Postoperative Pain

Robotic assisted laparoscopic prostatectomy (RALP) is the standard treatment for prostate cancer, due to the benefits of decreased blood loss and length of stay.The procedure involves removing a man's prostate using a minimally invasive robotic approach under the guidance of a surgeon.

laparoscopy
prostatectomy
prostate cancer
laparoscopic procedures
acetazolamide
  • 0 views
  • 16 Feb, 2024
  • 1 location
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

multiple myeloma
measurable disease
  • 0 views
  • 05 Aug, 2020
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.

metastasis
cancer
neutrophil count
liver metastasis
gilbert's syndrome
  • 0 views
  • 16 Feb, 2024
  • 1 location
Prostate Screening for Men With Inherited Risk of Developing Aggressive Prostate Cancer PATROL Study

This study investigates ways to detect prostate cancer earlier in men who are at increased genetic risk of developing prostate cancer that forms, grows, or spreads quickly (aggressive).

carcinoma
cancer treatment
ATM
digital rectal exam
cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer MIRAGE Study

This phase III trial studies compares CT-guided stereotactic body radiation therapy and MRI-guided stereotactic body radiation therapy (SBRT) in treating prostate cancer. Image-guided SBRT is a standard treatment for prostate cancer, which combines imaging of the cancer within the body with the delivery of therapeutic radiation doses produced on a …

prostate cancer
adenocarcinoma
stereotactic body radiation therapy
metastasis
cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Immune Profiling After HDR in Local Relapsed Prostate Cancer

The main-hypothesis is that HDR-brachytherapy will turn an immunologically "cold" (no T-cell infiltrations) prostate cancer into an immunologically "hot" (CD4 and CD8-cell infiltrations) tumor, creating leverage points for different forms of IO.

primary tumor
brachytherapy
multiparametric magnetic resonance imaging
tumor cells
  • 0 views
  • 16 Feb, 2024
  • 1 location
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

This phase II study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death.

prostate-specific antigen
stage iv prostate cancer
metastatic hormone refractory prostate cancer
carcinoma
metastatic malignant neoplasm
  • 0 views
  • 16 Feb, 2024
  • 1 location